Universal Health Services, Inc. (UHS) Down 5.7% — Time to Unwind the Position?
Universal Health Services, Inc. (UHS) is under heavy pressure on Tuesday, last changing hands at $175.17 on the NYSE. That is a $10.54 decline from the prior close of $185.71, a 5.68% drop that extends a long retreat in the shares. UHS now trades roughly 28.9% below its 52-week high of $246.33, reached on November 26, 2025. The stock has given back nearly a third of its value from that peak in under a year.
Volume stands at 645,250 shares with the session still open, about 82% of the 90-day average of 782,761. At that pace, turnover is on track to finish above normal levels by the close.
Why Universal Health Services, Inc. Price is Moving Lower
The selling traces back to HCA Healthcare (HCA). The largest for-profit hospital operator reported Q3 results on October 27, and its outlook unsettled investors across the group. On the surface, HCA's quarter was strong. Adjusted EPS came in at $7.22 against a $6.65 estimate, and revenue of $19.85 billion topped the $19.33 billion consensus.
The market focused on what came next. HCA said it expects 2026 results in the upper half of its existing guidance range, but signaled that 2027 earnings could be broadly flat. It also disclosed a roughly $400 million Q3 pretax hit from a rise in uninsured patients. On top of that, it projected a $550 million to $650 million reduction in Medicaid supplemental payments next year.
Those are industry-wide pressures, not problems unique to HCA. Investors marked down hospital operators accordingly. HCA shares fell 4.7% and Tenet Healthcare (THC) dropped 3.5% in afternoon trading, and UHS posted the steepest decline of the three. The damage stayed concentrated in operators rather than spreading across the broader Health Care sector. CVS Health Corporation (CVS) slipped 1.21% and UnitedHealth Group Incorporated (UNH) eased just 0.25%.
The timing adds to the caution. UHS was scheduled to report its own Q3 results after Tuesday's close, with the investor call set for October 28. That leaves shareholders reacting to a competitor's warning before seeing the company's numbers. Analysts expect EPS of about $5.15 to $5.19 on revenue of $4.71 billion. That would be a step down from the $5.69 EPS reported a year earlier, even with revenue growth of roughly 5%. With consensus already pointing to a year-over-year earnings decline, HCA's comments on uninsured volumes and Medicaid funding give investors one more reason to de-risk ahead of the release.
What is the Universal Health Services, Inc. Rating - Should I Sell?
Weiss Ratings assigns UHS a C+ rating. Current recommendation is Hold. The C+ sits at the upper end of the Hold range. It reflects a company whose operating fundamentals are notably stronger than its stock performance would suggest, though not strong enough to offset the market-driven risks that have weighed on the shares.
The fundamental case is solid across the board. UHS is rated Excellent on the Growth Index, supported by revenue growth of 8.27%. That is a healthy pace for a mature hospital and behavioral health operator, and it suggests patient volumes and pricing have held up. The Excellent Efficiency Index rating is backed by a 20.95% return on equity and an 8.42% profit margin, respectable figures in a business weighed down by labor costs, supply expenses, and reimbursement pressure. An Excellent rating on the Solvency Index indicates the balance sheet has room to absorb a softer reimbursement environment without strain. That matters given HCA's warning about Medicaid supplemental payments. With trailing EPS of $24.55 and a forward P/E of just 7.56, the valuation already prices in a good deal of skepticism.
Where the picture becomes more nuanced is in how the stock has actually behaved. UHS is rated Fair on the Total Return Index, which reflects a share price now nearly 29% below its November 2025 high. The Volatility Index is rated Weak. Today's 5.68% drop on a competitor's guidance, before UHS reported its own results, shows how sharply the shares react to sector-wide policy and reimbursement concerns. The Dividend Index is also rated Weak. A 0.43% yield gives shareholders little income to cushion swings of this size. These weaker dimensions keep the overall rating at C+ despite the strength of the underlying business.
Within the Health Care sector, Universal Health Services sits alongside CVS Health Corporation (CVS, C+). It ranks ahead of UnitedHealth Group Incorporated (UNH, C), Abbott Laboratories (ABT, C), and Stryker Corporation (SYK, C). That relative standing points to a slightly better risk/reward balance than several larger sector names, though it does not lift UHS out of Hold territory.
About Universal Health Services, Inc.
Universal Health Services, Inc. (UHS) is a Health Care company and one of the largest hospital management companies in the United States. Headquartered in King of Prussia, Pennsylvania, UHS operates through two main segments: acute care hospital services and behavioral health care services. Its facilities span the United States, Puerto Rico, the U.S. Virgin Islands, and the United Kingdom.
The acute care business runs general hospitals that provide emergency care, surgery, cardiology, oncology, obstetrics, and diagnostic services. That network is supported by freestanding emergency departments, outpatient surgery centers, and physician practices. UHS also operates Prominence Health Plan, a health insurance business that complements its provider network in certain markets.
The behavioral health segment is a key point of differentiation. UHS ranks among the largest operators of inpatient behavioral health facilities in the country, treating patients for psychiatric, substance use, and related conditions. In the United Kingdom, it operates through Cygnet Health Care. This scale in behavioral health, alongside its acute care footprint, gives UHS diversification that pure-play hospital operators lack. Even so, both segments depend heavily on payer mix, government reimbursement rates, and the cost and availability of clinical staff.
Investor Outlook
Universal Health Services, Inc. (UHS) carries a Weiss Rating of C+ (Hold). Today's sector-driven decline argues for patience rather than aggressive buying until the company's own outlook is clear. Investors should watch Q3 results and the October 28 call closely. The key points are management's commentary on uninsured patient volumes, its exposure to the Medicaid supplemental payment cuts HCA flagged, and any early read on 2027 earnings. See full rankings of all C+ rated Health Care stocks inside the Weiss Stock Screener.
--